THE
EMBO
JOURNAL

Metabolic regulation of pluripotency and germ cell fate through α−ketoglutarate

Julia Tischler, Wolfram H. Gruhn, John Reid, Edward Allgeyer, Florian Buettner, Carsten Marr, Fabian Theis, Ben D. Simons, Lorenz Wernisch, M Azim Surani

Review timeline:		
	Submission date:	27th Mar 2018
	Editorial Decision:	25th Apr 2018
	Revision received:	31st Jul 2018
	Editorial Decision:	17th Aug 2018
	Revision received:	24th Aug 2018
	Accepted:	27th Aug 2018

Editor: Daniel Klimmeck

Transaction Report:

(Note: With the exception of the correction of typographical or spelling errors that could be a source of ambiguity, letters and reports are not edited. The original formatting of letters and referee reports may not be reflected in this compilation.)

1st Editorial Decision   25th Apr 2018

Thank you for the submission of your manuscript (EMBOJ-2018-99518) to The EMBO Journal. Please accept my apologies for the delay in getting back to you due to delayed referee feedback. Your study has been sent to three referees, and we have received reports from all of them, which I enclose below.

As you will see, the referees acknowledge the potential high interest and novelty of your work, although they also express a number of concerns that will have to be addressed before they can support publication of your manuscript in The EMBO Journal. While referee #3 is overall positive and supportive, referee #1 states concerns about the claims made on relevance of aKG and oxidative phosphorylation for stem cell fate determination and asks you to corroborate your analyses (referee #1, pts 1,3). Along the same lines, this referee also requests analysis of protein levels and activities of enzymes involved in aKG synthesis (referee #1, pt. 2). Referee #2 agrees in that the causal link between aKG and control of differentiation is not sufficiently supported by the current data, and points to subtlety of effects and inconsistencies in the data. In addition, all referees list a number of technical and methods issues on assays used and controls made, as well as incomplete documentation, points that need to be addressed to achieve the level of robustness required for The EMBO Journal.

I judge the comments of the referees to be generally reasonable and we are in principle happy to invite you to revise your manuscript experimentally to address the referees' comments. I agree that your resource would strongly benefit from more in-depth analysis of the functional implication of aKG as opposed to other differential regulators.

REFEREE COMMENTS:

Referee #1:

In this manuscript 'Metabolic regulation of pluripotency and germ cell fate through alpha-ketoglutarate', Tischler et al investigate the transcriptomic dynamics during stem cell differentiation and influences of alpha-ketoglutarate (aKG) on stem cell fate determination. This is generally a solid study conducted at a high standard. The findings on aKG's roles in different stages of stem cell differentiation are interesting. However, the evidence that distinguish aKG from other factors that also change during stem cell differentiation are less solid than the other parts of this study.
1. As I mentioned above, the evidence from single cell RNA-seq are not strong enough to support the importance of alpha-ketoglutarate in stem cell fate determination. The only direct evidence is the down-regulation of Idh2 and up-regulation of Dlst during the ESC-to-EpiLC differentiation, but there are also other metabolic genes that have changes in their expression levels in this process. Moreover, the correlation between Dlst expression and the pseudotime (Fig 3A) is very subtle, suggesting that Dlst is not likely to be among the metabolic genes with the most dramatic changes. A comprehensive comparison among all genes considered in the pseudotime analysis will be helpful to clarify the importance of aKG.
2. The authors conclude that evidence demonstrating changes in expression levels of genes coding for enzymes involved in aKG generation distinguishes their study from previous recent reports showing the importance of aKG in regulating pluripotency (Fig EV1D). However, gene expression is not a direct indicator of enzyme level or activity. Thus, it would be more informative if protein level or enzyme activity was quantified and presented in these contexts.
3. Inhibition of glycolysis by 2-DG is used to validate the importance of OXPHOS in maintaining naïve pluripotency. This evidence is indirect and there is no other evidence showing that the inhibition of glycolysis results in enhanced OXPHOS.
4. More details of the computational methods are necessary. For instance, the software used to obtain the transcript counts needs to be reported. For the pseudotime analysis, it is also not clear what criterion is used to identify genes that change during the differentiation.
5. The authors claim that aKG can safeguard the transient epigenomic status during differentiation by maintaining histone methylation levels (Fig 4E). aKG is well known as a substrate of the aKG dependent histone and DNA demethylases. Thus, by intuition, adding aKG should lead to enhanced activity of these enzymes and loss of the histone methylation marks. However, Fig 4E shows that addition of aKG results in increased H3K27me3 levels. This is interesting but some discussion on possible mechanisms will be helpful.
6. The color scheme used in some figures (Fig 2B, 3B, etc) needs to be changed. It is very hard to see the difference between the two green colors used in these figures.

Referee #2:

Developmental potential of pluripotent stem cells (PSCs) is regulated by sophisticated molecular networks controlling their gene expression, epigenetic status as well as metabolic status. In this study, the author examined roles of energy metabolic status during development of naïve pluripotential ES cells (ESCs) into PGCLCs via primed epiblast-like cells (EpiLCs) in culture. They first found that glycolysis- and oxidative phosphorylation-related enzyme genes were up- and down-regulated, respectively, in the course of ESC differentiation to EpiSCs by single-cell RNA-seq, and also showed inhibition of glycolysis resulted in retention of ESCs undergoing conversion to EpiLCs in naïve status. The results together indicate the importance of glycolysis in primed PSCs, which is consistent to previous studies.
The authors then focused on aKG, a metabolite in the TCA cycle, because of down- and up-regulation of an aKG-producing enzyme gene, Idh2 and aKG-catobolizing enzyme gene, Dist, respectively, during EpiLC development from ESCs. Further investigation concerning roles of aKG indicated that aKG repressed conversion of ESCs to EpiLCs and partially replaced 2i for maintenance of naïve pluripotency of ESCs. The results also showed that addition of Citrate, an up-stream metabolite to aKG, but not a down-stream metabolite Succinate, repressed EpiLC development from ESCs, indicating the importance of levels of aKG among the TCA cycle metabolites for regulating EpiLC development. The authors then demonstrated that repression of EpiLC development by aKG did not necessarily depend on repression of cell cycle progression. aKG is a co-factor of H3K9me2 demethylases KDM3A and KDM3B and TET enzymes involved in DNA demethylation, and the results demonstrated that knock-down of Kdm3a/b or Tet1/2 repressed

the inhibitory effect of aKG for EpiLC development form ESCs, suggesting that aKG functions on EpiLC development via H3K9me2 and DNA methylation. The authors finally tested roles of aKG on PGCLC differentiation from EpiLCs, and found that aKG stimulated PGCLC formation from EpiLCs and partially replaced BMP4. In addition, aKG sustained the PGCLC competence in EpiLCs probably via affecting histone and DNA methylation.

This study revealed the importance of levels of aKG on EpiLC development from ESCs, PGCLC competence as well as PGCLC differentiation from EpiLCs, which should be highly interesting and important to understand roles of energy metabolisms on EpiLC and PGCLC development. Meanwhile experimental evidence showing direct linkage between aKG and regulation of epigenetic status in EpiLCs is weak.

Specific comments:
1. Fig.4E, Fig. EV6A, page 10, 2nd paragraph; Expected effects of addition of aKG are decreased H3K9me and H3K27me3. H3K9me2 is not significantly changes or is slightly decreased, if any, but H3K27me3 is clearly increased in dm-aKG treated cells compared with control cells both at 48 and 72 hr in Fig. 4E, which is not consistent with the expected functions of aKG. In addition, if aKG results in decreased H3K9me2, it may be more suitable to naïve status than primed EpiLCs status, which may also be inconsistent with prolonged PGCLC competence in EpiLCs in the presence of aKG. Please address those issues.

2. Fig.4, page 8-; Addition of dm-aKG enhanced PGCLC differentiation from EpiLCs, and it suggests that aKG is increased during PGCLC development. In that case, is the expression of Idh2 and Dist up- and down-regulated, respectively, in the course of PGCLC development?

Minor points:
1. Fig. EV4I; The graph shows relative colony formation in Kdm3a/b-KD condition over control with or without aKG, but in the absence of dm-KG, colonies may be rarely formed, and it is important to show increased colony formation by aKG without Kdm3a/b-KD and decreased aKG-induced colony formation by Kdm3a/b-KD. Therefore it may be more suitable to compare ratios of colony number in total number of plated cells in each condition.
2. The color codes may be inverted in the graphs in Fig. 3C, Fig.3H right panel.
3. Fig.3G left panel; EpiLCs in the legend may be ESCs w/o 2i.
4. page 9, 3rd paragraph, lines 1- 2; 'Addition of dm-aKG up to 24h after-----' may be 'Addition of dm-aKG from 24h to 48h after-----'.
5. page 12, lines 2-3; Please cite a reference or show data concerning OSN binding in Idh2.

Referee #3:

This is an excellent and novel manuscript that for the first time systematically tests the effect of aKG co-factor on distinct states of pluripotency, during their transition and in PGCs. This is a much needed study and set of results following the initial study by Carey e tal. Nature 2015 showing that Glutamine helps pluripotency via aKG production, however since then systematic characterization of aKG on pluripotency was missing (and in different states and during their transitions).

The authors use exacting reporters and cutting edge differentiation protocols (e.g. REX1-dGFP, Blimp1-mVenus and PGC reporters) to test the result and responsive genes to aKG. The establish beyond any doubt that aKG supports naive and PGC state and not the primed states. They do not stop there, but also show the importance of TET enzymes and KDm members to directly dictate the epigenetic state. They also establish difference in TCA cycle gene expression during naive to primed state, that supports the rationale for having aKG levels high in naive state.

The manuscript is very well written, and all conclusions are strongly supported by the results. I have no meaningful comments to add or experiments to requests, and support publishing this exciting and thorough study.

1st Revision - authors' response   31st Jul 2018

Rebuttal

General comments

We are most grateful for the Editorial guidance for the revisions, and thank the Reviewers for their suggestions and constructive comments. In response, we have performed additional experiments and made appropriate changes to the manuscript. These include comprehensive statistical analysis on our single-cell expression data to quantify transcript level changes during the conversion to EpiLC fate with respect to the 478 regulators with roles in cellular metabolism. Importantly, we measured levels of the αKG-generating enzyme IDH2 during the ESC-to-EpiLC transition to strengthen the connection between IDH2-mediated αKG synthesis and the regulation of pluripotency. We further confirm elevated IDH2 protein levels as readout of TCA cycle activity following glycolytic inhibition through 2-DG. We provide additional support for a link between αKG and the epigenetic state of EpiLCs through the locus-specific analysis of H3K9me2 and H3K27me3 modifications by ChIP-qPCR. Accordingly, we discuss the increase in H3K27me3 levels following dm-αKG supplementation and clarify the context-dependent roles of αKG in maintaining naïve pluripotency, and prolonging PGCLC competency, respectively.

Our specific comments follow:

Referee #1

In this manuscript 'Metabolic regulation of pluripotency and germ cell fate through alpha-ketoglutarate', Tischler et al investigate the transcriptomic dynamics during stem cell differentiation and influences of alpha-ketoglutarate (aKG) on stem cell fate determination. This is generally a solid study conducted at a high standard. The findings on aKG's roles in different stages of stem cell differentiation are interesting. However, the evidence that distinguish aKG from other factors that also change during stem cell differentiation are less solid than the other parts of this study.

1. As I mentioned above, the evidence from single cell RNA-seq are not strong enough to support the importance of alpha-ketoglutarate in stem cell fate determination. The only direct evidence is the down-regulation of Idh2 and up-regulation of Dlst during the ESC-to-EpiLC differentiation, but there are also other metabolic genes that have changes in their expression levels in this process. Moreover, the correlation between Dlst expression and the pseudotime (Fig 3A) is very subtle, suggesting that Dlst is not likely to be among the metabolic genes with the most dramatic changes. A comprehensive comparison among all genes considered in the pseudotime analysis will be helpful to clarify the importance of aKG.

We carried out a comprehensive statistical analysis of changes during the ESC-to-EpiLC transition of 478 transcripts linked to cellular metabolism, including 83 αKG-dependent dioxygenases, and of the key pluripotency (*Esrrb*, *Klf4*, *Nanog*, *Sox2*, and *Tfcp2l1*) and epiblast

fate (*Dnmt3b*, *Fgf5*, *Lin28b*) markers as references. We use the Kullback-Leibler (KL)-divergence between the genes' expression at an early (ESCs in 2i/Lif culture conditions) and a late (48h EpiLCs) stage, respectively, as a metric to quantify gene expression changes. Higher KL-scores represent larger changes in transcript levels. The KL-divergence has several properties that make it suitable for this purpose: it is invariant to shifting and scaling of the data; however, it is sensitive to changes in the variance of the pseudotime trajectory. Ordering all 478 transcripts by their KL-divergences, *Idh2* and *Dlst* regulators have high KL-scores ranked as the 23rd and 58th, respectively, supporting substantial changes in expression during the ESC-to-EpiLC transition (see Appendix Table S1). Importantly, we identify *Idh2* as the transcript with the top KL-score amongst all the TCA cycle genes analyzed, suggesting that the dynamic regulation of intracellular αKG levels through modulation of oxidative mitochondrial metabolism might be important for EpiLC differentiation. Indeed, we confirm this hypothesis through in-depth experimental validation. Genes with key roles in oxidative and glycolytic metabolism, respectively, rank comparably by our metric (i.e. KL-scores for *Cox7a1*, *Cpt1a*, and *Pdk1* rank at 13th, 17th, and 32nd, respectively).

We provide this data set as a rank-ordered list (by descending KL-scores) as Appendix Table S1. Accordingly, we refer to the comprehensive quantitative analysis in the main text (see page 4, first paragraph, lines 10-11, page 5, last paragraph, lines 1-3, and page 12, first paragraph, line 3). We provide details on the statistical analysis in the updated Methods section (see page 18, last paragraph). Furthermore, we acknowledge the less-pronounced change in *Dlst* transcript levels and now refer to it as 'slight' up regulation in the main text (see page 5, last paragraph, lines 2-3).

2. The authors conclude that evidence demonstrating changes in expression levels of genes coding for enzymes involved in aKG generation distinguishes their study from previous recent reports showing the importance of aKG in regulating pluripotency (Fig EV1D). However, gene expression is not a direct indicator of enzyme level or activity. Thus, it would be more informative if protein level or enzyme activity was quantified and presented in these contexts.

We measured IDH2 protein levels in naïve ESCs and at t=24h, 48h, and 72h during the EpiLC differentiation. Western blot analysis confirms the pronounced reduction of the αKG-generating enzyme during the ESC-to-EpiLC transition (see Fig EV3A to complement the pseudotime trajectory for *Idh2* in Fig 3A). We amend the text in our manuscript accordingly (see page 6, lines 2-3, and page 12, second paragraph, lines 3-5).

3. Inhibition of glycolysis by 2-DG is used to validate the importance of OXPHOS in maintaining naïve pluripotency. This evidence is indirect and there is no other evidence showing that the inhibition of glycolysis results in enhanced OXPHOS.

Principally, restriction of glycolysis requires cells to use alternative metabolic pathways to meet their energetic demands. We verify an increased dependency on mitochondrial oxidative metabolism following glycolytic inhibition by 2-DG in the context of the ESC-to-EpiLC transition: we confirm elevated IDH2 protein levels as readout of enhanced TCA cycle activity following 2-DG supplementation during the EpiLC differentiation (see Fig EV2A, referred to on page 5, line 6). A previous report indicated increased mitochondrial respiration after addition of 2-DG to mESCs cultures (Zhou et al., 2012). Note that up regulation of oxidative metabolism as an adaptive response to compensate for glycolytic inhibition by 2-DG has also been observed in various tumor-derived cell lines (Pusapati & Settleman, 2016, Sottnik, Lori et al., 2011).

4. More details of the computational methods are necessary. For instance, the software used in obtain the transcript counts needs to be reported. For the pseudotime analysis, it is also not clear what criterion is used to identify genes that change during the differentiation.

We include details on the software used to obtain single-cell transcript counts in the Revised Methods section (see page 17, first full paragraph, lines 6-8). In addition, we provide details on the computational and statistical methods employed for the comprehensive quantitative pseudotime analysis of 478 transcripts implicated in metabolic regulation (see page 18, last paragraph, and Appendix Table S1; please also see point 1 above).

5. The authors claim that aKG can safeguard the transient epigenomic status during differentiation by maintaining histone methylation levels (Fig 4E). aKG is well known as a substrate of the aKG dependent histone and DNA demethylases. Thus, by intuition, adding aKG should lead to enhanced activity of these enzymes and loss of the histone methylation marks. However, Fig 4E shows that addition of aKG results in increased H3K27me3 levels. This is interesting but some discussion on possible mechanisms will be helpful.

The transition from pre- to post-implantation epiblast *in vivo* entails rapid accumulation of the repressive H3K9me2 mark at promoters, gene bodies, and enhancers of developmentally linked genes, and concomitantly, a genome-wide reduction and redistribution of the repressive

H3K27me3 mark (Kurimoto, Yabuta et al., 2015, Zylicz, Dietmann et al., 2015). The ESC-to-EpiLC differentiation system *in vitro* faithfully recapitulates the histone methylation dynamics observed during this developmental transition (see Fig EV3A).

We propose that dm-αKG supplementation during the EpiLC induction sustains KDM3A and KDM3B activity, thereby counteracting the locus-specific accumulation of H3K9me2 (see Fig EV4H, I and Fig 4F). In addition, αKG likely supports the low-DNA methylation state by enhancing the efficiency of the DNA hydroxylases TET1 and TET2 (see Fig EV4J). Consequently, αKG plausibly prevents the genome-wide reduction in H3K27me3 that normally occurs during epiblast development, by further promoting its spreading at high CpG- regions (Zylicz et al., 2015).

Collectively, we show that αKG results in lower global H3K9me2 levels, which is consistent with a reduction of H3K9me2 levels at certain cis-regulatory elements (see Fig 4F; please also see point 1 below), and conversely, increased H3K27me3 levels (Fig 4E), in line with the characteristic epigenetic state of a relatively naïve cell state (Fig EV3A).

We discuss the possible counter-intuitive increase in H3K27me3 levels following addition of dm-αKG in the manuscript (see page 10, last paragraph, lines 7-10, and page 14, last paragraph).

Please also see our comments in response to Referee #2, point 1 below.

6. The color scheme used in some figures (Fig 2B, 3B, etc) needs to be changed. It is very hard to see the difference between the two green colors used in these figures.

We have amended the color scheme to improve the visibility of the differences in Fig 2B, 3B, and 3G.

Referee #2:

Developmental potential of pluripotential stem cells (PSCs) are regulated by sophisticated molecular networks controlling their gene expression, epigenetic status as well as metabolic status. In this study, the author examined roles of energy metabolic status during development of naïve pluripotential ES cells (ESCs) into PGCLCs via primed epiblast-like cells (EpiLCs) in culture.
They first found that glycolysis- and oxidative phosphorylation-related enzyme genes were up-

and down-regulated, respectively, in the course of ESC differentiation to EpiSCs by single-cell RNA-seq, and also showed inhibition of glycolysis resulted in retension of ESCs undergoing conversion to EpiLCs in naïve status. The results together indicate the importance of glycolysis in primed PSCs, which is consistent to previous studies.

The authors then focused on aKG, a metabolite in the TCA cycle, because of down- and up-regulation of an aKG-producing enzyme gene, Idh2 and aKG-catobolizing enzyme gene, Dist, respectively, during EpiLC development from ESCs. Further investigation concerning roles of aKG indicated that aKG repressed conversion of ESCs to EpiLCs and partially replaced 2i for maintenance of naïve pluripotency of ESCs. The results also showed that addition of Citrate, an up-stream metabolite to aKG, but not a down-stream metabolite Succinate, repressed EpiLC development from ESCs, indicating the importance of levels of aKG among the TCA cycle metabolites for regulating EpiLC development. The authors then demonstrated that repression of EpiLC development by aKG did not necessarily depend on repression of cell cycle progression. aKG is a co-factor of H3K9me2 demethylases KDM3A and KDM3B and TET enzymes involved in DNA demethylation, and the results demonstrated that knock-down of Kdm3a/b or Tet1/2 repressed the inhibitory effect of aKG for EpiLC development form ESCs, suggesting that aKG functions on EpiLC development via H3K9me2 and DNA methylation. The authors finally tested roles of aKG on PGCLC differentiation from EpiLCs, and found that aKG stimulated PGCLC formation from EpiLCs and partially replaced BMP4. In addition, aKG sustained the PGCLC competence in EpiLCs probably via affecting histone and DNA methylation.

This study revealed the importance of levels of aKG on EpiLC development from ESCs and on PGCLC competence as well as PGCLC differentiation from EpiLCs, which should be highly interesting and important to understand roles of energy metabolisms on EpiLC and PGCLC development. Meanwhile experimental evidence showing direct linkage between aKG and regulation of epigenetic status in EpiLCs is weak.

We greatly appreciate this feedback; we address the linkage between αKG and epigenetic state in more detail (see below).

Specific comments:
1. Fig.4E, Fig. EV6A, page 10, 2nd paragraph; Expected effects of addition of aKG are decreased H3K9me and H3K27me3. H3K9me2 is not significantly changes or is slightly decreased, if any, but H3K27me3 is clearly increased in dm-aKG treated cells compared with control cells both at 48 and 72 hr in Fig. 4E, which is not consistent with the expected functions of aKG

We acknowledge the comment and refer to our comment above (Referee #1, point 5).

The global changes in H3K9me2 levels following dm-αKG treatment are mild (Fig 4E), however, the conversion from naïve to primed pluripotency involves the acquisition of the H3K9me2 mark at promoters, gene bodies, and enhancers of some developmentally linked genes (Zylicz et al., 2015). We address this with reference to the locus-specific effects of dm-αKG supplementation during the EpiLC induction, by analyzing H3K9me2 and H3K27me3 modifications by ChIP-qPCR (see Fig 4F, Fig EV6D).

We find that dm-αKG opposes the accumulation of H3K9me2 on certain enhancer elements associated with the genes for the naïve pluripotent state (Zylicz et al., 2015), such as *Esrrb*, *Arid5b*, *Prdm14*, and *Nanog*. Consistent with this, levels for the repressive H3K27me3 mark are higher at these pluripotency-associated genes, except for *Prdm14*, where we detected no change. By contrast, we observe an inverse pattern, with high H3K9me2 and low H3K27me3, respectively, marking in the cis-regulatory region of *Pdgfa*. Notably, on loci, such as in the enhancer region of the germ cell-associated gene *Tfap2c*, H3K9me2 levels show an increase, while there also is an increase in the repressive H3K27me3 mark. This is consistent with repression of germline genes by both H3K9me2 and H3K27me3 during epiblast development (Kurimoto et al., 2015).

Altogether, while there is reduction in the global H3K9me2 levels following dm-αKG supplementation during the EpiLC induction, we observe a locus-specific effect of dm-αKG. Thus, a subset of cis-regulatory regions, in particular enhancer elements of pluripotency-associated genes have low levels of H3K9me2, but other regulatory regions, such as enhancers of the germ cell-associated gene *Tfap2c*, or the platelet-derived growth factor subunit A (*Pdgfa*), respectively, show an increase in H3K9me2 levels, irrespective of dm-αKG treatment. The locus-specific effect might reflect the selective recruitment of αKG-dependent H3K9me2 demethylases and the subtle changes in global H3K9me2 levels.

We present the results of these new ChIP-qPCR data on representative loci (*Esrrb*, *Arid5b*, *Tfap2c*, *Nanog*, *Prdm14*, and *Pdgfa*) in Fig 4F and Fig EV6D and in the text (see page 11, first full paragraph, page 11, second full paragraph, lines 4-8, and page 14, last paragraph, lines 4-6); we provide technical details in the Methods section (see page 24, last paragraph, continued on page 25).

In addition, if aKG results in decreased H3K9me2, it may be more suitable to naïve status than primed EpiLCs status, which may also be inconsistent with prolonged PGCLC competence in EpiLCs in the presence of aKG. Please address those issues.

We agree that αKG plays an important role in maintaining naïve pluripotency, as we demonstrate through its inhibitory effect on the conversion to the primed pluripotent state and its ability to partially replace 2i inhibitors in sustaining an embryonic stem cell (ESC) state. The addition of dm-αKG even at t=24h of EpiLC stimulation, results in the majority of cells retaining a *Rex1*-GFP positive state (see attached Figure); consequently, there is a reduction in the efficiency of PGCLC specification (Fig EV6A, EV6B). By contrast, the addition of dm-αKG at t=48h of EpiLC differentiation, at the time when cells start to become competent for the PGCLC fate, promotes and extends the duration of the competent state to 72h, but without a change in the efficiency of the PGCLC induction (Fig 4C, Fig EV6C). Note that in the control EpiLCs, the competent state for the specification of *Prdm1*-GFP positive PGCLCs largely declines after 48h.

We propose a relative balance between H3K9me2 and H3K27me3 as being a key to the developmental competence for the PGC fate, which is apparently sustained for a longer period by dm-αKG. Of note, dm-αKG supplementation at the time of competence does not restore the very low H3K9me2 levels to those detected in naïve ESCs. Instead, αKG conceivably counteracts the differentiation-stimulating bFGF & ActivinA signaling and maintains equilibrium between H3K9me2 removal through activating αKG-dependent H3K9me2 demethylases, and differentiation-induced H3K9me2 accumulation at certain loci, and consequently, prevents the global reduction of H3K27me3. This proposal merits further investigation in the future.

We discuss the dual functions of αKG in sustaining the naïve pluripotent state and in extending the developmental competence for the PGC fate, respectively, in detail (see page 14, second and third full paragraphs, and page 15, first full paragraph).

2. Fig.4, page 8-; Addition of dm-aKG enhanced PGCLC differentiation from EpiLCs, and it suggests that aKG is increased during PGCLC development. In that case, is the expression of Idh2 and Dist up- and down-regulated, respectively, in the course of PGCLC development?

We investigated expression levels of key regulators implicated in oxidative metabolism (*Cox7a1*, *Cpt1a*), αKG synthesis (*Idh2*), and glycolysis (*Pdk1*, *Pdk3*) during PGCLC development by qRT PCR analysis. We find *Cox7a1* and *Idh2* to be up regulated in day4 PGCLC, in line with an enhanced oxidative metabolism and increased αKG generation during PGC development. This is

also consistent with a recent report from our group, showing that *Idh2* transcript levels reach a maximum in E9.5 *ex vivo*-isolated PGCs (Hackett, Sengupta et al., 2013).

We include the new data set as Fig EV5A and refer to it in the main text (see page 9, first paragraph, lines 2-8, and page 14, first paragraph, lines 5-6).

Minor points:
1. Fig. EV4I; The graph shows relative colony formation in Kdm3a/b-KD condition over control with or without aKG, but in the absence of dm-KG, colonies may be rarely formed, and it is important to show increased colony formation by aKG without Kdm3a/b-KD and decreased aKG-induced colony formation by Kdm3a/b-KD. Therefore it may be more suitable to compare ratios of colony number in total number of plated cells in each condition.

We present bright-field images of AP-stained colonies at the bottom of the figure panel, which represent the low colony forming ability of DMSO-treated control cells, the enhanced colony formation after addition of dm-αKG during EpiLC induction, and the attenuation of the dm-αKG-induced effect upon knockdown of *Kdm3a/b*, respectively. However, we consider it more appropriate to graphically represent the relative colony formation after *Kdm3a/b* knockdown, normalized to the non-targeting control, in both conditions (dm-αKG and DMSO, respectively).

2. The color codes may be inverted in the graphs in Fig. 3C, Fig.3H right panel.

We have corrected this error.

3. Fig.3G left panel; EpiLCs in the legend may be ESCs w/o 2i.

We have amended the legend accordingly.

4. page 9, 3rd paragraph, lines 1- 2; 'Addition of dm-aKG up to 24h after-----' may be 'Addition of dm-aKG from 24h to 48h after-----'.

We have modified the sentence as suggested.

5. page 12, lines 2-3; Please cite a reference or show data concerning OSN binding in Idh2.

We now show data on OSN binding within a region of 20Kb upstream to 4Kb downstream of the transcriptional start site of *Idh2*; by contrast, we do not find this to be the case for *Idh1,* and *Dlst*. Please see graphical representations (see Appendix Figure S1), and our reference to it in the text (see page 12, last paragraph, lines 14-15, continued on page 13, lines 1-3). We provide details on evaluating OSN binding, including the three references to the ChIP-seq data sets we have analyzed, in the Methods section (see page 25, last paragraph, continued on page 26).

Referee #3:

This is an excellent and novel manuscript that for the first time systematically tests the effect of aKG co-factor on distinct states of pluripotency, during their transition and in PGCs. This is a much needed study and set of results following the initial study by Carey e tal. Nature 2015 showing that Glutamine helps pluripotency via aKG production, however since then systematic characterization of aKG on pluripotency was missing (and in different states and during their transitions).

The authors use exacting reporters and cutting edge differentiation protocols (e.g. REX1-dGFP, Blimp1-mVenus and PGC reporters) to test the result and responsive genes to aKG. The establish beyond any doubt that aKG supports naive and PGC state and not the primed states. They do not stop there, but also show the importance of TET enzymes and KDm members to directly dictate the epigenetic state. They also establish difference in TCA cycle gene expression during naive to primed state, that supports the rationale for having aKG levels high in naive state.

The manuscript is very well written, and all conclusions are strongly supported by the results. I have no meaningful comments to add or experiments to requests, and support publishing this exciting and thorough study.

We acknowledge and appreciate the supportive comments by the Reviewer.

References

Hackett JA, Sengupta R, Zylicz JJ, Murakami K, Lee C, Down TA, Surani MA (2013) Germline DNA Demethylation Dynamics and Imprint Erasure Through 5-Hydroxymethylcytosine. Science 339: 448-452

Kurimoto K, Yabuta Y, Hayashi K, Ohta H, Kiyonari H, Mitani T, Moritoki Y, Kohri K, Kimura H, Yamamoto T, Katou Y, Shirahige K, Saitou M (2015) Quantitative Dynamics of Chromatin Remodeling during Germ Cell Specification from Mouse Embryonic Stem Cells. Cell Stem Cell 16: 517-532

Pusapati R, Settleman J (2016) TORquing metabolic reprogramming in cancer cells. Cell Cycle 15: 2387-2388

Sottnik JL, Lori JC, Rose BJ, Thamm DH (2011) Glycolysis inhibition by 2-deoxy-d-glucose reverts the metastatic phenotype in vitro and in vivo. Clin Exp Metastas 28: 865-875

Zhou W, Choi M, Margineantu D, Margaretha L, Hesson J, Cavanaugh C, Blau CA, Horwitz MS, Hockenbery D, Ware C, Ruohola-Baker H (2012) HIF1alpha induced switch from bivalent to exclusively glycolytic metabolism during ESC-to-EpiSC/hESC transition. EMBO J 31: 2103-16

Zylicz JJ, Dietmann S, Gunesdogan U, Hackett JA, Cougot D, Lee C, Surani MA (2015) Chromatin dynamics and the role of G9a in gene regulation and enhancer silencing during early mouse development. Elife 4

Figure 1. Addition of dm-αKG at t=24h to t=48h during the ESC-to-EpiLC transition retains a *Rex1*-high state. Shown is the fraction of *Rex1*-GFPd2 cells, following dm-αKG supplementation from t=24h, averaged over duplicate experiments. Error bars indicate ± SE.

Thank you for submitting your revised manuscript for consideration by The EMBO Journal. Your revised study was sent back to two of the original referees for re-evaluation, and we have received comments from both of them, which I enclose below. As you will see the referees find that their concerns have been sufficiently addressed and they are now broadly favour of publication.

Thus, we are pleased to inform you that your manuscript has been accepted in principle for publication in The EMBO Journal, pending some minor issues regarding formatting of the study as outlined below, which need to be adjusted at re-submission.

REFEREE COMMENTS:

Referee #1:

My concerns have been adequately addressed. This is a very topical paper.

Referee #2:

All of my concerns have been appropriately addressed in the revised manuscript.

EMBO PRESS

PLEASE NOTE THAT THIS CHECKLIST WILL BE PUBLISHED ALONGSIDE YOUR PAPER

Corresponding Author Name: M Azim Surani
Journal Submitted to: EMBO Journal
Manuscript Number: EMBOJ-2018-99518

Reporting Checklist For Life Sciences Articles (Rev. June 2017)

This checklist is used to ensure good reporting standards and to improve the reproducibility of published results. These guidelines are consistent with the Principles and Guidelines for Reporting Preclinical Research issued by the NIH in 2014. Please follow the journal's authorship guidelines in preparing your manuscript.

A- Figures
1. Data
The data shown in figures should satisfy the following conditions:

→ the data were obtained and processed according to the field's best practice and are presented to reflect the results of the experiments in an accurate and unbiased manner.
→ figure panels include only data points, measurements or observations that can be compared to each other in a scientifically meaningful way.
→ graphs include clearly labeled error bars for independent experiments and sample sizes. Unless justified, error bars should not be shown for technical replicates.
→ if n< 5, the individual data points from each experiment should be plotted and any statistical test employed should be justified
→ Source Data should be included to report the data underlying graphs. Please follow the guidelines set out in the author ship guidelines on Data Presentation.

2. Captions

Each figure caption should contain the following information, for each panel where they are relevant:

→ a specification of the experimental system investigated (eg cell line, species name).
→ the assay(s) and method(s) used to carry out the reported observations and measurements
→ an explicit mention of the biological and chemical entity(ies) that are being measured.
→ an explicit mention of the biological and chemical entity(ies) that are altered/varied/perturbed in a controlled manner.

→ the exact sample size (n) for each experimental group/condition, given as a number, not a range;
→ a description of the sample collection allowing the reader to understand whether the samples represent technical or biological replicates (including how many animals, litters, cultures, etc.).
→ a statement of how many times the experiment shown was independently replicated in the laboratory.
→ definitions of statistical methods and measures:
  • common tests, such as t-test (please specify whether paired vs. unpaired), simple χ2 tests, Wilcoxon and Mann-Whitney tests, can be unambiguously identified by name only, but more complex techniques should be described in the methods section;
  • are tests one-sided or two-sided?
  • are there adjustments for multiple comparisons?
  • exact statistical test results, e.g., P values = x but not P values < x;
  • definition of 'center values' as median or average;
  • definition of error bars as s.d. or s.e.m.

Any descriptions too long for the figure legend should be included in the methods section and/or with the source data.

B- Statistics and general methods

Question	Answer
1.a. How was the sample size chosen to ensure adequate power to detect a pre-specified effect size?	We performed all experiments in up to six independent biolgical replicates. Our sample sizes adhere to the standard in the field, for the experimental techniques employed.
1.b. For animal studies, include a statement about sample size estimate even if no statistical methods were used.	NA
2. Describe inclusion/exclusion criteria if samples or animals were excluded from the analysis. Were the criteria pre-established?	NA
3. Were any steps taken to minimize the effects of subjective bias when allocating animals/samples to treatment (e.g. randomization procedure)? If yes, please describe.	NA
For animal studies, include a statement about randomization even if no randomization was used.	NA
4.a. Were any steps taken to minimize the effects of subjective bias during group allocation or/and when assessing results (e.g. blinding of the investigator)? If yes please describe.	NA
4.b. For animal studies, include a statement about blinding even if no blinding was done	NA
5. For every figure, are statistical tests justified as appropriate?	YES, we used the standard heteroscedastic t-test for the data analysed (see Methods).
Do the data meet the assumptions of the tests (e.g., normal distribution)? Describe any methods used to assess it.	We visually inspected some representative data using Q-Q plots to test for normality.
Is there an estimate of variation within each group of data?	NA (due to heteroscedasticity of test)
Is the variance similar between the groups that are being statistically compared?	NA (due to heteroscedasticity of test)

C- Reagents

6. To show that antibodies were profiled for use in the system under study (assay and species), provide a citation, catalog number and/or clone number, supplementary information or reference to an antibody validation profile. e.g., Antibodypedia (see link list at top right), 1DegreeBio (see link list at top right).	We are providing catalog numbers for all antibodies used in this study in the respective sections ('Mitochondria labelling', 'Western blot analysis', 'ChIP-qPCR analysis') within the Methods section of our manuscript.
7. Identify the source of cell lines and report if they were recently authenticated (e.g., by STR profiling) and tested for mycoplasma contamination.	We are listing all cell lines used in this study, including the specific clones when applicable, and their source within the section 'Cell lines' within the Methods section of our manuscript.

* for all hyperlinks, please see the table at the top right of the document

D- Animal Models

8. Report species, strain, gender, age of animals and genetic modification status where applicable. Please detail housing and husbandry conditions and the source of animals.	NA
9. For experiments involving live vertebrates, include a statement of compliance with ethical regulations and identify the committee(s) approving the experiments.	NA
10. We recommend consulting the ARRIVE guidelines (see link list at top right) (PLoS Biol. 8(6), e1000412, 2010) to ensure that other relevant aspects of animal studies are adequately reported. See author guidelines, under 'Reporting Guidelines'. See also: NIH (see link list at top right) and MRC (see link list at top right) recommendations. Please confirm compliance.	NA

E- Human Subjects

11. Identify the committee(s) approving the study protocol.	NA
12. Include a statement confirming that informed consent was obtained from all subjects and that the experiments conformed to the principles set out in the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report.	NA
13. For publication of patient photos, include a statement confirming that consent to publish was obtained.	NA
14. Report any restrictions on the availability (and/or on the use) of human data or samples.	NA
15. Report the clinical trial registration number (at ClinicalTrials.gov or equivalent), where applicable.	NA
16. For phase II and III randomized controlled trials, please refer to the CONSORT flow diagram (see link list at top right) and submit the CONSORT checklist (see link list at top right) with your submission. See author guidelines, under 'Reporting Guidelines'. Please confirm you have submitted this list.	NA
17. For tumor marker prognostic studies, we recommend that you follow the REMARK reporting guidelines (see link list at top right). See author guidelines, under 'Reporting Guidelines'. Please confirm you have followed these guidelines.	NA

F- Data Accessibility

18. Provide a "Data Availability" section at the end of the Materials & Methods, listing the accession codes for data generated in this study and deposited in a public database (e.g. RNA-Seq data: Gene Expression Omnibus GSE39462, Proteomics data: PRIDE PXD000208 etc.) Please refer to our author guidelines for 'Data Deposition'. Data deposition in a public repository is mandatory for: a. Protein, DNA and RNA sequences b. Macromolecular structures c. Crystallographic data for small molecules d. Functional genomics data e. Proteomics and molecular interactions	We have deposited the single-cell RNA-Seq data generated in this study under accession number GSE107761 in the Gene Expression Omnibus database. We specify the accession number under 'Data availability' at the end of the Methods section.
19. Deposition is strongly recommended for any datasets that are central and integral to the study; please consider the journal's data policy. If no structured public repository exists for a given data type, we encourage the provision of datasets in the manuscript as a Supplementary Document (see author guidelines under 'Expanded View' or in unstructured repositories such as Dryad (see link list at top right) or Figshare (see link list at top right).	See section F-18 above.
20. Access to human clinical and genomic datasets should be provided with as few restrictions as possible while respecting ethical obligations to the patients and relevant medical and legal issues. If practically possible and compatible with the individual consent agreement used in the study, such data should be deposited in one of the major public access-controlled repositories such as dbGAP (see link list at top right) or EGA (see link list at top right).	NA
21. Computational models that are central and integral to a study should be shared without restrictions and provided in a machine-readable form. The relevant accession numbers or links should be provided. When possible, standardized format (SBML, CellML) should be used instead of scripts (e.g. MATLAB). Authors are strongly encouraged to follow the MIRIAM guidelines (see link list at top right) and deposit their model in a public database such as Biomodels (see link list at top right) or JWS Online (see link list at top right). If computer source code is provided with the paper, it should be deposited in a public repository or included in supplementary information.	All models used are already published as open access and are freely available (please see Methods for more details and specific parameter settings).

G- Dual use research of concern

22. Could your study fall under dual use research restrictions? Please check biosecurity documents (see link list at top right) and list of select agents and toxins (APHIS/CDC) (see link list at top right). According to our biosecurity guidelines, provide a statement only if it could.	NA